Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.60
+0.72 (5.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $1.57M in the twelve months ending September 30, 2024. In the year 2023, Inhibrx Biosciences had annual revenue of $1.63M with 24.26% growth.
Revenue (ttm)
$1.57M
Revenue Growth
+24.26%
P/S Ratio
134.79
Revenue / Employee
$9,116
Employees
172
Market Cap
211.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.63M | 319.00K | 24.26% |
| Dec 31, 2022 | 1.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 5 weeks ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 6 weeks ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
- 6 weeks ago - Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - PRNewsWire
- 4 months ago - Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying - Benzinga
- 4 months ago - Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - PRNewsWire
- 7 months ago - Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi - Seeking Alpha
- 7 months ago - Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
- 7 months ago - Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi - PRNewsWire